相关实验视频

Updated: Jul 5, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

FSTL3与肺腺癌的预后和免疫细胞透有关

Xiangzhi Meng¹, Xiaojian Zhao¹, Boxuan Zhou¹

¹Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Panjiayuan, Nanli 17, Beijing, 100021, People's Republic of China.

Journal of cancer research and clinical oncology

|January 19, 2024

概括

富利斯塔丁类3 (FSTL3) 在肺腺癌中降低,影响患者的预后和免疫细胞透. 准FSTL3为新型肺癌免疫疗法提供了潜力.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

在各种癌症中,利他类3 (FSTL3) 表达的失调.
FSTL3在肺腺癌 (LUAD) 发病过程中的特定作用及其对瘤免疫力的影响在很大程度上仍未被探索.

研究的目的:

调查FSTL3表达与肺腺癌的临床特征之间的关联.
在肺腺癌样本中探索FSTL3与免疫细胞透的相关性.

主要方法:

从癌症基因组图谱 (TCGA) 和医院验证队列中分析肺腺癌数据.
利用生物信息学工具 (GEPIA,TIMER) 和免疫组织化学来评估FSTL3表达,临床相关性和免疫细胞透.

主要成果:

肺腺癌患者的FSTL3表达显著降低.
FSTL3水平与N阶段,病态阶段,总体存活率和B细胞,T细胞,NK细胞和中性粒细胞的透相关.
相关基因 (KRT6A,VEGFC,KRT14,KRT17,SNORA12,KRT81) 影响了LUAD的预后.

结论:

FSTL3是肺腺癌进展,预后和免疫微环境调节的重要因素.
准FSTL3及其相关基因为肺腺癌免疫治疗提供了一个有希望的策略.

关键词:

在FSTL3中使用.免疫细胞的透.肺部腺癌瘤是肺部腺癌.预测预后预测预测

更多相关视频

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Published on: July 29, 2017

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...